Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antisense transcript of PTP4A3, liver carcinoma survival associated (ASTILCS)
- Target
- ASTILCS
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
ASTILCS is a long non-coding RNA (lncRNA) transcribed antisense to PTP4A3 and is overexpressed in hepatocellular carcinoma (HCC) cells and tissues[1][3][6]. It was identified as essential for HCC cell survival in functional genetic screens, where its knockdown led to induction of apoptosis and suppression of cell proliferation[4]. ASTILCS is believed to regulate the expression of its neighboring gene, PTK2, which encodes Protein Tyrosine Kinase 2, a key survival factor for HCC cells. Its biological role appears restricted to cellular regulation processes critical for tumor growth and survival, making it a putative therapeutic target and prognostic biomarker for liver cancer[4].
- Other names
- AntiSense Transcript Important for Liver Carcinoma SurvivalAC100803.2LOC105375790
02
Mechanism of action
Loss-of-function (knockdown) with shRNA, antisense oligonucleotides, or CRISPRi induces apoptosis in HCC cells via downregulation of neighboring gene PTK2 (Protein Tyrosine Kinase 2)
03
Biological functions
Regulation of cell proliferationRegulation of apoptosisRegulation of gene expression (in cis)
04
Disease associations
Cancer, specifically hepatocellular carcinoma (HCC)
05
Safety considerations
Potential challenges include the specificity of targeting lncRNAs and risk of off-target gene regulation or impact on neighboring gene PTK2
06
Biomarkers
Overexpression in hepatocellular carcinoma tissue versus normal liver tissue
Beyond the preview
Go deeper on Antisense transcript of PTP4A3, liver carcinoma survival associated (ASTILCS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antisense transcript of PTP4A3, liver carcinoma survival associated (ASTILCS).